PhaseBio Pharmaceuticals Inc. (NASDAQ:PHAS) shares, rose in value on Friday, 08/05/22, with the stock price up by 1.61% to the previous day’s close as strong demand from buyers drove the stock to $1.26.
Actively observing the price movement in the last trading, the stock closed the session at $1.24, falling within a range of $1.20 and $1.36. The value of beta (5-year monthly) was 2.05. Referring to stock’s 52-week performance, its high was $4.10, and the low was $0.50. On the whole, PHAS has fluctuated by 40.00% over the past month.
With the market capitalization of PhaseBio Pharmaceuticals Inc. currently standing at about $61.31 million, investors are eagerly awaiting this quarter’s results, scheduled for Nov 10, 2021. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.31, which is expected to increase to -$0.26 for fiscal year -$1.07 and then to about -$1.21 by fiscal year 2023. Data indicates that the EPS growth is expected to be 64.10% in 2023, while the next year’s EPS growth is forecast to be -13.10%.
According to the average forecast, sales growth in current quarter could jump down -92.00%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2023, the company’s y-o-y revenues would reach $15.62 million, representing an increase of 44.20% from the revenues reported in the last year’s results.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that PHAS’s technical picture suggests that short-term indicators denote the stock is a 50% Buy on average. However, medium term indicators have put the stock in the category of 50% Sell while long term indicators on average have been pointing out that it is a Hold.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of PHAS currently trading nearly 17.47% and 48.95% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 63.35, while the 7-day volatility ratio is showing 11.73% which for the 30-day chart, stands at 15.45%. Furthermore, PhaseBio Pharmaceuticals Inc. (PHAS)’s beta value is 2.45, and its average true range (ATR) is 0.14.
Data on historical trading for PhaseBio Pharmaceuticals Inc. (NASDAQ:PHAS) indicates that the trading volumes over the past 10 days have averaged 0.21 million and over the past 3 months, they’ve averaged 477.17K. According to company’s latest data on outstanding shares, there are 48.63 million shares outstanding.
Nearly 0.60% of PhaseBio Pharmaceuticals Inc.’s shares belong to company insiders and institutional investors own 67.90% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 2.1 million shares as on Jul 14, 2022, resulting in a short ratio of 3.67. According to the data, the short interest in PhaseBio Pharmaceuticals Inc. (PHAS) stood at 4.32% of shares outstanding as of Jul 14, 2022; the number of short shares registered in Jun 14, 2022 reached 2.28 million. The stock has fallen by -51.72% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the PHAS stock heading into the next quarter.